EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Increased serologic reactivity with automated CMIA testing and its implications for deceased donor eligibility determination in the United States

Sara O Dionne, Hillary C S R Akana, Michael Real, Kimberly A Elliott, Brenden R O'Neale

Cell and Tissue Banking · 08.09.2025 · 26 (3)

DOI: 10.1007/s10561-025-10193-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell and Tissue Banking, online erschienen am 08.09.2025. Verfasst von Sara O Dionne und 4 weiteren Autor:innen. Beteiligte Einrichtung: Eurofins Donor & Product Testing, LLC, Centennial, CO, USA. Hauptthemen laut MEDLINE: Tissue Donors, Donor Selection, Luminescent Measurements, Serologic Tests. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the United States, the use of Food & Drug Administration (FDA)-licensed, approved, or cleared tests is required for infectious disease screening and determining the eligibility of deceased donors for all Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). With the discontinuation of two manual enzyme-linked immunoassay (EIA) tests, automated Chemiluminescent Microparticle Immunoassay (CMIA) technology was introduced as the primary alternative. This study compares serologic reactivity rates between manual EIA and automated CMIA methods. Serology testing was performed on blood specimens from deceased tissue and cornea donors using either manual EIA assays or automated CMIA platforms. A retrospective analysis of over 160,000 donors was conducted to evaluate assay-specific reactive rates. Concordance between serology and Nucleic Acid Testing (NAT) results was also assessed. Reactive rates for HBsAg, HIV-1/2 antibodies, and HTLV-I/II antibodies increased following the transition to CMIA-based testing compared to manual EIA methods. However, these increases were not associated with a corresponding rise in NAT reactive results, indicating a potential increase in false-positive or non-viremic results. Automated testing offers improved quality control and reduces variability associated with manual techniques. However, the shift to CMIA assays resulted in a higher number of reactive serology results, leading to increased donor ineligibility despite negative NAT results. The data presented here highlights the potential impact on donor deferral rates for tissue and cornea donors due to assay platform changes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tissue DonorsDonor SelectionLuminescent MeasurementsSerologic TestsHumansUnited StatesRetrospective StudiesImmunoassayAutomation

Stichwörter der Autor:innen

Chemiluminescent microparticle immunoassay (CMIA)Donor eligibilityHuman cells, tissues and cellular and tissue-based products (HCT/Ps)Nucleic acid testingSerology testing

Autor:innen und Institutionen

  • Eurofins Donor & Product Testing, LLC, Centennial, CO, USA.
  • Eurofins Donor & Product Testing, LLC, Centennial, CO, USA. Hillary.akana@dpt.eurofinsus.com.
  • MTF Biologics, Edison, NJ, USA.

Zitieren

APA

Dionne, S. O., Akana, H. C. S. R., Real, M., Elliott, K. A., & O'Neale, B. R. (2025). Increased serologic reactivity with automated CMIA testing and its implications for deceased donor eligibility determination in the United States. Cell and Tissue Banking, 26(3). https://doi.org/10.1007/s10561-025-10193-0

Vancouver

Dionne SO, Akana HCSR, Real M, Elliott KA, O'Neale BR. Increased serologic reactivity with automated CMIA testing and its implications for deceased donor eligibility determination in the United States. Cell and Tissue Banking. 2025;26(3). doi:10.1007/s10561-025-10193-0

BibTeX
@article{Dionne2025,
  author = {Dionne, Sara O and Akana, Hillary C S R and Real, Michael and Elliott, Kimberly A and O'Neale, Brenden R},
  title = {Increased serologic reactivity with automated CMIA testing and its implications for deceased donor eligibility determination in the United States},
  journal = {Cell and Tissue Banking},
  year = {2025},
  volume = {26},
  number = {3},
  doi = {10.1007/s10561-025-10193-0}
}
Kostenlos starten →